Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2012

Study Completion Date

July 31, 2012

Conditions
Multiple Sclerosis
Interventions
DRUG

Dalfampridine-ER 5mg

5mg, twice daily

DRUG

Dalfampridine-ER 10mg

10mg, twice daily

OTHER

Placebo

placebo, twice daily

Trial Locations (70)

Unknown

North Central Neurology Associates, PC, Cullman

Phoenix Neurological Associates, Ltd, Phoenix

Arizona Neurological Institute, Sun City

Clinical Research Advantage Inc., Tempe

Sutter East Bay Physicians Medical Foundation, Berkeley

Neuro-Pain Medical Center, Inc., Fresno

Loma Linda University Medical Center, Loma Linda

Collaborative NeuroScience Network, Inc., Long Beach

University of California Davis Medical Center, Sacramento

Mount Sinai Rehabilitation Hospital, Hartford

Georgetown University Hospital, Washington D.C.

Neurology Associates, PA, Maitland

University of Miami School of Medicine, Dept. of Neurology, Miami

Neurological Associates, Pompano Beach

Neurologique Foundation, Inc., Ponte Vedra

Negroski, Sutherland and Hanes Neurology, Sarasota

Suncoast Neuroscience Associates, Inc., St. Petersburg

Tallahassee Neurological Clinic, PA, Tallahassee

Axiom Clinical Research of Florida, Tampa

The Multiple Sclerosis Center of Vero Beach, Vero Beach

Sheperd Center, Inc., Atlanta

Northwestern University, Chicago

Consultants in Neurology Ltd., Northbrook

Indiana University School of Medicine, Indianapolis

Josephson Wallack Munshower Neurology, PC, Indianapolis

Methodist Plaza Specialty, Des Moines

Ruan Neurology Clinic and Research Center, Des Moines

The University of Kansas Medical Center, Kansas City

Associates in Neurology, PSC, Lexington

University of Maryland, Maryland Center for Multiple Sclerosis, Baltimore

Lahey Clinic, Lexington

Springfield Neurology Associates, LLC, Springfield

Wayne State University, Detroit

Advanced Neurology Specialists, Great Falls

Veterans Administration Sierra Neveda Health Care System, Reno

Upstate Clinical Research, LLC, Albany

NYU Langone Medical Center MS Comprehensive Care Center, New York

Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates, Patchogue

Island Neurological Associates, PC, Plainview

University of Rochester Medical Center, Rochester

PMG Research of Charlotte, Charlotte

The Neurological Institute, PA, Charlotte

PMG Research of Hickory, LLC, Hickory

Raleigh Neurology Associates, Raleigh

PMG Research of Winston-Salem, Winston-Salem

Altru Health System Clinic, Grand Forks

Northern Ohio Neuroscience, LLC, Bellevue

Cleveland Clinic Foundation, Cleveland

Neurological Research Institute, Columbus

Ohio State University, Columbus, Columbus

Neurology Specialists, Inc., Dayton

OMRF Multiple Sclerosis Center of Excellence, Oklahoma City

Oregon Health and Science University, Portland

Providence Multiple Sclerosis Center, Portland

The Pennsylvania State University, Milton S. Hershey Medical Center, Hershey

Hospital of the University of Pennsylvania, Philadelphia

Temple University School of Medicine, Philadelphia

The Neurology Foundation, Inc., Providence

Wesley Neurology Clinic, PC, Cordova

Advanced Neurosciences Institute, Franklin

Sibyl E. Wray, MD, Neurology, PC, Knoxville

Texas Neurology, PA, Dallas

Kelsey-Seybold Clinic, Houston

Maxine Mesinger Multiple Sclerosis Clinic; Baylor College of Medicine, Houston

Fletcher Allen Health Care, Burlington

Hampton Roads Neurology, Newport News

Neurological Associates, Richmond

Virginia Commonwealth University, Richmond

Swedish Neuroscience Institute, Seattle

Aurora Saint Luke's Medical Center, Milwaukee

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY

NCT01328379 - Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter